Literature DB >> 8470534

Furosemide VOR test for the detection of endolymphatic hydrops.

M Ito1, Y Watanabe, H Shojaku, H Kobayashi, S Aso, K Mizukoshi.   

Abstract

In order to detect endolymphatic hydrops, we applied three neuro-otologic examination methods, including the furosemide VOR test, the glycerol dehydration test, and electrocochleography in 61 patients with unilateral Menière's disease, 21 patients with delayed endolymphatic hydrops, and 10 patients with syphilitic labyrinthitis. The positive rate of the furosemide VOR test in patients with endolymphatic hydrops was more than 50%. Inconsistencies were observed between the results of the furosemide VOR test, the glycerol test and/or electrocochleography. Therefore, combined test battery of these tests is useful clinically for detecting endolymphatic hydrops in the vestibular and cochlear systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470534     DOI: 10.3109/00016489309128123

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  3 in total

1.  Comparison of the diagnostic value of 3 T MRI after intratympanic injection of GBCA, electrocochleography, and the glycerol test in patients with Meniere's disease.

Authors:  Hisakuni Fukuoka; Yutaka Takumi; Keita Tsukada; Maiko Miyagawa; Tomohiro Oguchi; Hitoshi Ueda; Masumi Kadoya; Shin-ichi Usami
Journal:  Acta Otolaryngol       Date:  2011-12-27       Impact factor: 1.494

2.  Recent and Frequent Vertigo Attacks Produce Negative Findings on Furosemide-Loading Vestibular Evoked Myogenic Potential Testing in Meniere's Disease.

Authors:  Toru Seo; Ko Shiraishi; Takaaki Kobayashi; Takeshi Fujita; Kazuya Saito; Katsumi Doi
Journal:  Front Neurol       Date:  2018-08-03       Impact factor: 4.003

Review 3.  The Clinical Utility of Vestibular-Evoked Myogenic Potentials in the Diagnosis of Ménière's Disease.

Authors:  Maxime Maheu; Jenny Marylin Alvarado-Umanzor; Audrey Delcenserie; François Champoux
Journal:  Front Neurol       Date:  2017-08-15       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.